309 related articles for article (PubMed ID: 20367669)
1. Sodium L-ascorbyl-2-phosphate 5% lotion for the treatment of acne vulgaris: a randomized, double-blind, controlled trial.
Woolery-Lloyd H; Baumann L; Ikeno H
J Cosmet Dermatol; 2010 Mar; 9(1):22-7. PubMed ID: 20367669
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, randomized, placebo-controlled study of a lotion containing triethyl citrate and ethyl linoleate in the treatment of acne vulgaris.
Charakida A; Charakida M; Chu AC
Br J Dermatol; 2007 Sep; 157(3):569-74. PubMed ID: 17635508
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study.
Eichenfield LF; Alió Sáenz AB
J Drugs Dermatol; 2011 Dec; 10(12):1382-96. PubMed ID: 22134562
[TBL] [Abstract][Full Text] [Related]
4. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
[TBL] [Abstract][Full Text] [Related]
5. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment.
Leyden JJ; Shalita A; Thiboutot D; Washenik K; Webster G
Clin Ther; 2005 Feb; 27(2):216-24. PubMed ID: 15811485
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial.
Stainer R; Matthews S; Arshad SH; McDonald S; Robinson J; Schapira C; Foote KD; Baird-Snell M; Gregory T; Pollock I; Stevens MT; Edwards AM
Br J Dermatol; 2005 Feb; 152(2):334-41. PubMed ID: 15727648
[TBL] [Abstract][Full Text] [Related]
7. Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies.
Eichenfield LF; Jarratt M; Schlessinger J; Kempers S; Manna V; Hwa J; Liu Y; Graeber M;
J Drugs Dermatol; 2010 Jun; 9(6):639-46. PubMed ID: 20645525
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Feldman SR; Werner CP; Alió Saenz AB
J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
Leyden J; Thiboutot DM; Shalita AR; Webster G; Washenik K; Strober BE; Shupack J
Arch Dermatol; 2006 May; 142(5):605-12. PubMed ID: 16702498
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy for acne vulgaris: a randomized, controlled, split-face clinical trial of topical aminolevulinic acid and pulsed dye laser therapy.
Orringer JS; Sachs DL; Bailey E; Kang S; Hamilton T; Voorhees JJ
J Cosmet Dermatol; 2010 Mar; 9(1):28-34. PubMed ID: 20367670
[TBL] [Abstract][Full Text] [Related]
11. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial.
Berger R; Rizer R; Barba A; Wilson D; Stewart D; Grossman R; Nighland M; Weiss J
Clin Ther; 2007 Jun; 29(6):1086-97. PubMed ID: 17692723
[TBL] [Abstract][Full Text] [Related]
12. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris.
Leyden JJ; Krochmal L; Yaroshinsky A
J Am Acad Dermatol; 2006 Jan; 54(1):73-81. PubMed ID: 16384759
[TBL] [Abstract][Full Text] [Related]
13. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris.
Draelos ZD; Carter E; Maloney JM; Elewski B; Poulin Y; Lynde C; Garrett S;
J Am Acad Dermatol; 2007 Mar; 56(3):439.e1-10. PubMed ID: 17208334
[TBL] [Abstract][Full Text] [Related]
14. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
Cook-Bolden FE; Gold MH; Guenin E
J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
[TBL] [Abstract][Full Text] [Related]
15. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
Tanghetti EA; Werschler WP; Lain T; Guenin E; Martin G; Pillai R
J Drugs Dermatol; 2020 Jan; 19(1):70-77. PubMed ID: 31985914
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
Harper JC; Baldwin H; Stein Gold L; Guenin E
J Drugs Dermatol; 2019 Nov; 18(11):1147-1154. PubMed ID: 31741360
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical efficacies of sodium ascorbyl phosphate, retinol and their combination in acne treatment.
Ruamrak C; Lourith N; Natakankitkul S
Int J Cosmet Sci; 2009 Feb; 31(1):41-6. PubMed ID: 19134126
[TBL] [Abstract][Full Text] [Related]
18. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older.
Tyring SK; Kircik LH; Pariser DM; Guenin E; Bhatt V; Pillai R
J Drugs Dermatol; 2018 Oct; 17(10):1084-1091. PubMed ID: 30365589
[TBL] [Abstract][Full Text] [Related]
19. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy.
Thiboutot DM; Fleischer AB; Del Rosso JQ; Rich P
J Drugs Dermatol; 2009 Jul; 8(7):639-48. PubMed ID: 19588640
[TBL] [Abstract][Full Text] [Related]
20. Topical epidermal growth factor for the improvement of acne lesions: a randomized, double-blinded, placebo-controlled, split-face trial.
Kim HK; Yeo IK; Li K; Kim BJ; Kim MN; Hong CK
Int J Dermatol; 2014 Aug; 53(8):1031-6. PubMed ID: 24962549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
